Market Overview

UPDATE: UBS Investment Research Reduces PT to $42 on Pentair on Q2 Weather Headwinds to Pump Sales

Related PNR
Biotechs Among Stocks That Insiders Have Been Buying Lately
Earnings Scheduled For October 20, 2015
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q3 2015 Update (Seeking Alpha)

UBS Investment Research reiterated its Neutral rating on Pentair (NYSE: PNR) and lowered its price target from $46 to $42 on sales headwinds for the second quarter.

UBS Investment Research noted, "We think a dry 2Q hurt weather-related U.S. pump sales, and weaker mfg data suggests down side to Tech Prod. Euro macro, FX pressures likely became more severe in 2Q, but we think PNR's lowered outlook at 1Q helps mitigate risk to estimates. Warm, dry weather likely helped Pool, and the April Sibrape deal could add 2-3 points to 2Q-4Q sales growth (not in our estimates). We also see 2Q tailwinds on net price, better CPT margins, and mix shift in TP away from telecom."

Pentair closed at $38.30 on Tuesday.

Latest Ratings for PNR

Oct 2015Stifel NicolausDowngradesBuy
Oct 2015Morgan StanleyInitiates Coverage onEqual-weight
Oct 2015Goldman SachsReinstatesNeutral

View More Analyst Ratings for PNR
View the Latest Analyst Ratings

Posted-In: UBS Investment ResearchAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings


Related Articles (PNR)

Get Benzinga's Newsletters